Frontlight ResearchEarly access
Taking people in GermanyPhase 1
Testing ATI-052 in adults with mild to moderate asthma
Tests a single dose of ATI-052 in adults with mild to moderate asthma.
Key facts
- Who runs it
- Aclaris Therapeutics Inc.
- Where
- Berlin and Luebeck, GermanySee the 2 sites
- Trial code
- Registry title
- A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 4 May 2026
- Expected to end
- 9 Dec 2026
- Type of study
- Interventional
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild to moderate asthma to test the safety and effects of a single dose of ATI-052.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Mild to moderate asthma
Where in Germany
- Parexel International GmbHBerlin, GermanyTaking people
- Velocity Clinical Research Germany GmbHLuebeck, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing ATI-052 in adults with mild to moderate asthmaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 November 2026